GLP-3 16MG

GLP-3 16MG

$303.00

GLP-3 is a multi-receptor agonist peptide designed to target multiple pathways for weight management and metabolic health. By activating receptors related to glucose regulation, appetite control, and energy expenditure, GLP-3 offers a comprehensive approach to managing obesity, type 2 diabetes, and other metabolic disorders. It is gaining attention for its potential to promote significant weight loss and improve overall metabolic function, making it a promising option in both clinical and therapeutic settings.

Available on backorder

Quantity Discount / Amount Price
Summary
GLP-3 16MG$303.00
$303.00

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

GLP-3 (LY3437943) is a novel synthetic peptide that acts as a triple agonist, targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This unique mechanism of action makes it a promising candidate for the treatment of obesity and related metabolic disorders. GLP-3 is designed to mimic the effects of three naturally occurring hormones involved in metabolism and appetite regulation, potentially offering superior weight loss and metabolic benefits compared to single or dual agonist therapies.

Sequence:Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)

Molecular Formula:C78H121N21O23S2

Molecular Weight:4731.33 g/mol

CAS Number:2381089-83-2

  1. Weight Loss Efficacy: In a 48-week phase 2 obesity study, GLP-3 demonstrated significant weight reductions of 22.8% and 24.2% at doses of 8 mg and 12 mg, respectively.
  2. Liver Fat Reduction: At 24 weeks, GLP-3 showed dose-dependent reductions in liver fat content: -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), and -82.4% (12 mg).
  3. Metabolic Improvements: Treatment with GLP-3 resulted in improvements in cardiometabolic measures, including hemoglobin A1c, fasting blood glucose, insulin, blood pressure, and lipid profiles.
  4. Normalization of Glycemia: At week 48, 72% of participants in the GLP-3 groups achieved normoglycemia (HbA1c < 5.7%), compared to only 22% in the placebo group.
  5. Structural Insights: Cryo-EM studies revealed that GLP-3 adopts a single continuous helix that penetrates the core of the receptor transmembrane domain, providing insights into its triple agonism mechanism.

  1. Long-term Safety and Efficacy: Extended studies are needed to evaluate the long-term effects and safety profile of GLP-3 in various patient populations.
  2. Combination Therapies: Exploring potential synergistic effects of GLP-3 with other therapeutic agents could open new avenues for treatment in obesity and related disorders.
  3. Expanded Clinical Applications: Investigation into GLP-3's potential benefits in conditions such as type 2 diabetes, non-alcoholic steatohepatitis (NASH), and cardiovascular disease is warranted.
  4. Optimal Dosing Regimens: Further research into optimal delivery methods and dosing regimens for different conditions could enhance the therapeutic potential of GLP-3.
  5. Mechanism of Action: Additional studies to fully elucidate the molecular mechanisms by which GLP-3 exerts its diverse effects across different tissue types are needed.

  1. Sanyal, A.J., et al. (2024). Triple hormone receptor agonist GLP-3 for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30(7), 2037-2048. [Online].
    Available: https://www.nature.com/articles/s41591-024-03018-2
  2. Wang, L., et al. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR by GLP-3. Cell Discovery, 10, 16. [Online]
    Available https://www.nature.com/articles/s41421-024-00700-0
  3. Jastreboff, A.M., et al. (2023). Triple–Hormone-Receptor Agonist GLP-3 for Obesity. New England Journal of Medicine. [Online].
    Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  4. Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10844714/
  5. Novo Pro Labs. (2023). GLP-3 (LY3437943), 99% purity peptide (TFA removed). [Online].
    Available: https://www.novoprolabs.com/p/retatrutide-ly3437943--319206.html